Damora Therapeutics targets mutCALR in ET/MF with potent DMR-001 and CLARITY-101 timelines, funded into 2029. Read my analysis for more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results